For research use only. Not for therapeutic Use.
Prolgolimab（Cat No.:I042083）is an investigational monoclonal antibody being explored for cancer immunotherapy. It targets PD-1 (programmed cell death protein 1), a checkpoint receptor on T cells that suppresses immune responses against tumors. By blocking PD-1, prolgolimab aims to enhance T cell activity, allowing the immune system to better identify and attack cancer cells. It is being studied in clinical trials for various types of cancer, including melanoma, non-small cell lung cancer, and other solid tumors. Prolgolimab is part of the growing class of immuno-oncology agents focused on checkpoint inhibition.
| Catalog Number | I042083 |
| CAS Number | 2093956-19-3 |
| Purity | ≥95% |
